{"id":46927,"date":"2022-08-04T13:01:37","date_gmt":"2022-08-04T11:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/"},"modified":"2022-08-04T13:01:37","modified_gmt":"2022-08-04T11:01:37","slug":"seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/","title":{"rendered":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc<\/a>. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET.\n<\/p>\n

\nAn audio webcast of the presentation will be available under the \u201cInvestors and News\u201d section of Seres\u2019 website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.\n<\/p>\n

\nAbout Seres Therapeutics<\/b>\n<\/p>\n

\nSeres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres\u2019 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile<\/i> infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.\n<\/p>\n

\nFor more information, please visit www.serestherapeutics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPR<\/b>
Kristin Ainsworth
\n
kainsworth@serestherapeutics.com<\/a><\/p>\n

IR<\/b>
Carlo Tanzi, Ph.D.
\n
ctanzi@serestherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the \u201cInvestors … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46927","6":"format-standard","7":"category-industry"},"yoast_head":"\nSeres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the \u201cInvestors ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-04T11:01:37+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference\",\"datePublished\":\"2022-08-04T11:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/\"},\"wordCount\":264,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/\",\"name\":\"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-04T11:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the \u201cInvestors ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-04T11:01:37+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference","datePublished":"2022-08-04T11:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/"},"wordCount":264,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/","url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/","name":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-04T11:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-present-at-canaccord-genuity-42nd-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46927"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46927\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}